Phase I Study of HXN6005 in Adult Healthy Participants

Summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetic characteristics and pharmacodynamics of HXN6005 in Healthy Participants. Researchers will compare HXN6005 to a placebo (a look-alike substance that contains no drug). Participants will take a single dose of HXN6005 or placebo on Day 1, and visit the clinic for followup and tests per the protocol scheme.

Timeline

Start

2026-04-27

Primary completion

2027-03-13

Completion

2027-03-13

Drugs

Indications

No indication recorded.